EA202090179A1 - Композиции и способы модуляции роста волос - Google Patents

Композиции и способы модуляции роста волос

Info

Publication number
EA202090179A1
EA202090179A1 EA202090179A EA202090179A EA202090179A1 EA 202090179 A1 EA202090179 A1 EA 202090179A1 EA 202090179 A EA202090179 A EA 202090179A EA 202090179 A EA202090179 A EA 202090179A EA 202090179 A1 EA202090179 A1 EA 202090179A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hair growth
methods
modulation
compositions
relates
Prior art date
Application number
EA202090179A
Other languages
English (en)
Inventor
Уилльям И. Лоури
Майкл И. Дзунг
Хитер Кристофк
Сяогуан Лю
Original Assignee
Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния filed Critical Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния
Publication of EA202090179A1 publication Critical patent/EA202090179A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
    • A61K8/492—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid having condensed rings, e.g. indol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/69—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing fluorine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/69—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing fluorine
    • A61K8/70—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing fluorine containing perfluoro groups, e.g. perfluoroethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/41—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by carboxyl groups, other than cyano groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/22—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/26—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/57—Nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/535—Organo-phosphoranes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Настоящее изобретение относится к соединениям, которые способны ингибировать митохондриальный переносчик пирувата и стимулировать рост волос. Настоящее изобретение также относится к способам стимулирования роста волос или лечения состояний или расстройств, влияющих на рост волос, таких как облысение или алопеция.
EA202090179A 2017-06-30 2018-06-29 Композиции и способы модуляции роста волос EA202090179A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762527775P 2017-06-30 2017-06-30
US201862654095P 2018-04-06 2018-04-06
PCT/US2018/040385 WO2019006359A1 (en) 2017-06-30 2018-06-29 COMPOSITIONS AND METHODS FOR MODULATION OF HAIR GROWTH

Publications (1)

Publication Number Publication Date
EA202090179A1 true EA202090179A1 (ru) 2020-04-24

Family

ID=64742233

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090179A EA202090179A1 (ru) 2017-06-30 2018-06-29 Композиции и способы модуляции роста волос

Country Status (15)

Country Link
US (4) US11312714B2 (ru)
EP (1) EP3644989A4 (ru)
JP (2) JP7221227B2 (ru)
KR (2) KR102642823B1 (ru)
CN (2) CN116120314A (ru)
AR (1) AR114075A1 (ru)
AU (2) AU2018294351B2 (ru)
BR (1) BR112019026080A8 (ru)
CA (1) CA3067746A1 (ru)
CL (1) CL2019003886A1 (ru)
EA (1) EA202090179A1 (ru)
IL (2) IL271443B2 (ru)
MX (2) MX2019015475A (ru)
PE (1) PE20200743A1 (ru)
WO (1) WO2019006359A1 (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102440809B1 (ko) 2017-02-24 2022-09-05 더 리전트 오브 더 유니버시티 오브 캘리포니아 Mpc 저해제를 사용하여 모발 성장을 촉진하는 조성물 및 방법
WO2019006359A1 (en) 2017-06-30 2019-01-03 The Regents Of The University Of California COMPOSITIONS AND METHODS FOR MODULATION OF HAIR GROWTH
JP2022516136A (ja) * 2019-01-02 2022-02-24 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 毛髪の成長を調節するための組成物及び方法
KR20220128361A (ko) * 2019-12-20 2022-09-20 더 리전트 오브 더 유니버시티 오브 캘리포니아 모발 성장을 촉진하기 위한 화합물의 합성
FR3105222B1 (fr) * 2019-12-20 2022-06-03 Nunii Laboratoire Inhibiteur du transporteur MCT7/SLC16A6 pour son utilisation pour la régulation de la pigmentation cutanée et une composition comprenant ledit inhibiteur
WO2021253013A2 (en) * 2020-06-12 2021-12-16 Rekindle Therapeutics Inc. Modulators of e3 ligases
EP4172159A4 (en) * 2020-06-30 2024-01-10 Univ California COMPOSITIONS AND METHODS FOR MODULATING HAIR GROWTH
WO2022006039A1 (en) * 2020-06-30 2022-01-06 The Regents Of The University Of California Compositions and methods for modulating hair growth
WO2023129854A1 (en) 2021-12-29 2023-07-06 Pelage Pharmaceuticals, Inc. Compounds for treatment of hair loss
WO2023130024A1 (en) * 2021-12-29 2023-07-06 Pelage Pharmaceuticals, Inc. Compounds for treatment of hair loss
WO2023191515A1 (ko) * 2022-03-29 2023-10-05 연세대학교 산학협력단 인디루빈 유도체 및 대사활성화제를 포함하는 탈모 방지 또는 발모 촉진용 조성물
CN116251086A (zh) * 2023-02-15 2023-06-13 江西中医药大学 乳酸及其衍生物在促毛发生长及缓解脱发中的应用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0235746B2 (ja) 1983-03-07 1990-08-13 Sagami Chem Res 33chikantetorafuruoroindoorujudotai
US4680413A (en) * 1986-01-17 1987-07-14 Nippon Soda Co., Ltd. Process for the production of 3-phenyl-4-cyanopyrroles
GB8913708D0 (en) * 1989-06-14 1989-08-02 Unilever Plc Cosmetic composition
GB9014221D0 (en) 1990-06-26 1990-08-15 Janssen Pharmaceutica Nv Method of treating alopecia
GB9023585D0 (en) 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds
GB9226855D0 (en) * 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
GB9412719D0 (en) * 1994-06-24 1994-08-17 Erba Carlo Spa Substituted azaindolylidene compounds and process for their preparation
JPH09176162A (ja) 1995-12-22 1997-07-08 Toubishi Yakuhin Kogyo Kk チアゾリジンジオン誘導体及びその製造法並びにそれを含む医薬組成物
FR2796274B1 (fr) * 1999-07-16 2001-09-21 Oreal Utilisation de l'acide 4,6-dimethoxy-indole 2-carboxylique ou de ses derives pour stimuler ou induire la pousse des cheveux et/ou stopper leur chute
US6416777B1 (en) 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
AU2001239826B2 (en) 2000-02-23 2006-06-15 Orentreich Foundation For The Advancement Of Science, Inc. Methods and compositions for the treatment of alopecia and other disorders of the pilosebaceous apparatus
EP1408966B1 (en) 2001-07-17 2008-02-20 N-Gene Research Laboratories Inc. Synergistic pharmaceutical combinations for the prevention or treatment of diabetes
EP1605967A1 (en) * 2003-03-13 2005-12-21 Novo Nordisk A/S Novel nph insulin preparations
WO2005123664A2 (en) 2004-06-14 2005-12-29 Wyeth Processes for the preparation of 2-cyano-3-naphthalene-1-yl-acrylic acid alkyl or benzyl esters
MY144903A (en) 2004-06-17 2011-11-30 Novartis Ag Pyrrolopyridine derivatives and their use as crth2 antagonists
ES2312012T3 (es) 2004-09-17 2009-02-16 Biomas Ltd. Nuevos compuestos de telurio y su uso como inmunomodulares.
DK1848431T3 (en) 2005-02-09 2016-04-18 Santen Pharmaceutical Co Ltd LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS
CA2611577A1 (en) 2005-06-07 2007-09-07 Foamix Ltd. Antibiotic kit and composition and uses thereof
JP5007304B2 (ja) 2005-06-22 2012-08-22 プレキシコン，インコーポレーテッド キナーゼ調節のための化合物および方法，およびその適応症
GB0525337D0 (en) 2005-12-13 2006-01-18 Novartis Ag Organic compounds
US9308181B2 (en) 2006-03-06 2016-04-12 Nuvo Research Inc. Topical formulations, systems and methods
US8343962B2 (en) 2006-03-06 2013-01-01 Nuvo Research Inc. Topical formulation
CL2007002516A1 (es) 2006-08-31 2008-05-16 Smithkline Beecham Corp Compuestos derivados de indol indano; composicion farmaceutica; y su uso para tratar hiperglicemia, diabetes tipo 2, tolerancia deteriorada a la glucosa, resistencia a la insulina, sindrome x, dislipidemia.
US20080064765A1 (en) 2006-09-11 2008-03-13 Jacob Birnbaum Novel hair growth compositions and methods for treating hair loss or related claims
WO2009030257A1 (en) 2007-09-05 2009-03-12 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Methods and compounds for treating diseases caused by reactive oxygen species
US20130023587A1 (en) 2010-04-01 2013-01-24 Duke University Compositions and methods for the treatment of cancer
JP2014500275A (ja) 2010-12-06 2014-01-09 フォリカ，インコーポレイテッド 禿頭症を治療するため、および毛髪の成長を促進するための方法
US9453014B2 (en) * 2011-12-22 2016-09-27 Connexios Life Sciences Pvt. Ltd. Cyclic amide derivatives as inhibitors of 11-β-hydroxysteroid dehydrogenase and uses thereof
EP2847356A4 (en) 2012-05-10 2015-08-05 Univ Utah Res Found COMPOSITIONS AND METHODS FOR MODULATING THE ACTIVITY OF A MITOCHONDRIAL PYRUVATE CARRIER
WO2013185214A1 (en) 2012-06-11 2013-12-19 Universite Laval Pla2g7/lp-pla2 as biomarker and therapeutic target in the prevention and treatment of calcific aortic valve disease
EP2859004A4 (en) 2012-06-12 2016-03-02 Univ California FLUORATION OF ARYLIC COMPOUNDS
WO2014207213A1 (en) 2013-06-28 2014-12-31 Medizinische Universität Innsbruck Novel inhibitors of protein kinase c epsilon signaling
WO2015049365A2 (en) * 2013-10-03 2015-04-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for modulating autophagy in a subject in need thereof
US9636340B2 (en) 2013-11-12 2017-05-02 Ayyappan K. Rajasekaran Kinase inhibitors
CA2936551A1 (en) 2014-01-24 2015-07-30 Confluence Life Sciences, Inc. Substituted pyrrolopyridines and pyrrolopyrazines for treating cancer or inflammatory diseases
US20190135747A1 (en) 2016-05-12 2019-05-09 Regents Of The University Of Minnesota Indole and indazole cyanocinnamate compounds and therapeutic uses thereof
WO2018039612A1 (en) * 2016-08-26 2018-03-01 The Regents Of The University Of California Compositions and methods for promoting hair growth with mpc1 inhibitors
AU2017314836A1 (en) * 2016-08-26 2019-03-21 The Regents Of The University Of California Hair follicle stem cell activation and hair growth
JP2020504740A (ja) 2016-12-22 2020-02-13 マブファーマ，インク． ホスホジエステラーゼ阻害剤および微生物処置の方法
KR102440809B1 (ko) 2017-02-24 2022-09-05 더 리전트 오브 더 유니버시티 오브 캘리포니아 Mpc 저해제를 사용하여 모발 성장을 촉진하는 조성물 및 방법
CN106880693A (zh) 2017-03-22 2017-06-23 广州国草夏方生物科技有限公司 一种治疗脂溢性脱发的生发液组合物及其制备方法
WO2019006359A1 (en) 2017-06-30 2019-01-03 The Regents Of The University Of California COMPOSITIONS AND METHODS FOR MODULATION OF HAIR GROWTH
JP2020536048A (ja) 2017-09-29 2020-12-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 発毛を調節するための組成物及び方法
JP2022516136A (ja) 2019-01-02 2022-02-24 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 毛髪の成長を調節するための組成物及び方法
US20220079899A1 (en) 2019-01-14 2022-03-17 The Regents Of The University Of California Compositions and methods for treating ocular conditions
US20220079900A1 (en) 2019-01-14 2022-03-17 The Regents Of The University Of California Compositions and methods for treating cardiac injury
KR20220128361A (ko) 2019-12-20 2022-09-20 더 리전트 오브 더 유니버시티 오브 캘리포니아 모발 성장을 촉진하기 위한 화합물의 합성
WO2022006039A1 (en) 2020-06-30 2022-01-06 The Regents Of The University Of California Compositions and methods for modulating hair growth
EP4172159A4 (en) 2020-06-30 2024-01-10 Univ California COMPOSITIONS AND METHODS FOR MODULATING HAIR GROWTH

Also Published As

Publication number Publication date
WO2019006359A1 (en) 2019-01-03
IL305317A (en) 2023-10-01
MX2019015475A (es) 2020-02-19
NZ759233A (en) 2023-08-25
JP2020526484A (ja) 2020-08-31
US20200157093A1 (en) 2020-05-21
JP2023061995A (ja) 2023-05-02
US11472804B2 (en) 2022-10-18
IL271443A (en) 2020-01-30
AR114075A1 (es) 2020-07-15
BR112019026080A8 (pt) 2022-11-22
KR102642823B1 (ko) 2024-03-04
US20240025895A1 (en) 2024-01-25
CA3067746A1 (en) 2019-01-03
PE20200743A1 (es) 2020-07-24
CL2019003886A1 (es) 2020-05-22
CN116120314A (zh) 2023-05-16
BR112019026080A2 (pt) 2020-06-30
KR20200022480A (ko) 2020-03-03
EP3644989A1 (en) 2020-05-06
US11312714B2 (en) 2022-04-26
AU2018294351B2 (en) 2022-12-22
MX2022007823A (es) 2022-07-19
IL271443B1 (en) 2023-09-01
JP7221227B2 (ja) 2023-02-13
IL271443B2 (en) 2024-01-01
AU2023201669A1 (en) 2023-04-13
EP3644989A4 (en) 2021-07-14
US20220153738A1 (en) 2022-05-19
AU2018294351A1 (en) 2019-12-05
US20230114220A1 (en) 2023-04-13
CN110944634A (zh) 2020-03-31
US11787804B2 (en) 2023-10-17
KR20240033119A (ko) 2024-03-12

Similar Documents

Publication Publication Date Title
EA202090179A1 (ru) Композиции и способы модуляции роста волос
MX2021008089A (es) Composiciones y metodos para modular el crecimiento del cabello.
EA201891910A1 (ru) Гетероарильные ингибиторы pad4
EA201991862A1 (ru) Композиции и способы, предназначенные для лечения гемоглобинопатий
EA202092590A1 (ru) Пиридазиноны в качестве ингибиторов parp7
EA201892147A1 (ru) Бициклические соединения
EA201990912A1 (ru) Анти-lag-3 антитела и их композиции
EA033395B1 (ru) Ингибиторы индоламин-2,3-диоксигеназы и способы их применения
EA201990221A1 (ru) 1,3-дигидроксифенильные производные, применимые в качестве иммуномодуляторов
PH12015502028A1 (en) Ido inhibitors
EA201891251A1 (ru) Бициклические ингибиторы pad4
MX2015017486A (es) Inhibidores de indolamina 2,3-dioxigenasa (dio).
MX366875B (es) Inhibidores de indoleamina 2,3-dioxigenasa (ido).
EA201790806A1 (ru) Иммунорегулирующие средства
MX2015011374A (es) Inhibidores de indolamina 2,3-dioxigenasa (ido).
MX2016002075A (es) Inhibidores de indolamina 2,3-dioxigenasa (ido).
PH12020500300A1 (en) Compositions and methods for modulating hair growth
EA201891347A1 (ru) Аза-бензимидазольные ингибиторы pad4
EA201990257A1 (ru) Фракции плазмы крови в качестве лечения когнитивных расстройств, связанных со старением
EA201892225A1 (ru) АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ
MX2017015923A (es) Inhibidores de indolamina-2,3-dioxigenasa (ido).
EA202190464A1 (ru) Замещенные бензимидазолы в качестве ингибиторов pad4
EA201690690A1 (ru) Способ придания волосам определённой формы
EA202091742A1 (ru) ПРОИЗВОДНЫЕ ХРОМЕНА В КАЧЕСТВЕ ИНГИБИТОРОВ ВЗАИМОДЕЙСТВИЯ TCR-Nck
EA201790430A1 (ru) С-20 стероидные соединения, композиции и их применение для лечения травматического повреждения головного мозга (tbi), включая сотрясения мозга